Gritstone bio, Inc. Stock

Equities

GRTS

US39868T1051

Pharmaceuticals

Real-time Estimate Cboe BZX 09:50:17 2024-06-17 EDT 5-day change 1st Jan Change
0.774 USD -1.02% Intraday chart for Gritstone bio, Inc. +8.10% -60.95%
Sales 2024 * 16.53M 22.72M Sales 2025 * 44.87M 61.67M Capitalization 84.9M 117M
Net income 2024 * -135M -186M Net income 2025 * -140M -192M EV / Sales 2024 * 5.99 x
Net Debt 2024 * 14.18M 19.49M Net cash position 2025 * 49.85M 68.52M EV / Sales 2025 * 0.78 x
P/E ratio 2024 *
-0.77 x
P/E ratio 2025 *
-0.88 x
Employees 231
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.02%
1 week+8.10%
Current month+2.96%
1 month+1.17%
3 months-67.75%
6 months-55.25%
Current year-60.95%
More quotes
1 week
0.72
Extreme 0.7235
0.83
1 month
0.70
Extreme 0.701
0.86
Current year
0.67
Extreme 0.6716
3.17
1 year
0.67
Extreme 0.6716
3.33
3 years
0.67
Extreme 0.6716
14.42
5 years
0.67
Extreme 0.6716
35.20
10 years
0.67
Extreme 0.6716
35.20
More quotes
Managers TitleAgeSince
Founder 57 15-07-31
Director of Finance/CFO 44 21-06-22
Chief Tech/Sci/R&D Officer 59 16-04-12
Members of the board TitleAgeSince
Founder 57 15-07-31
Chairman 69 19-09-11
Director/Board Member 77 22-08-11
More insiders
Date Price Change Volume
24-06-17 0.7966 +1.87% 6 341
24-06-14 0.782 -1.76% 752,696
24-06-13 0.796 -0.82% 500,145
24-06-12 0.8026 +0.77% 643,583
24-06-11 0.7965 +8.09% 906,125

Delayed Quote Nasdaq, June 17, 2024 at 09:31 am

More quotes
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.782 USD
Average target price
3.833 USD
Spread / Average Target
+390.20%
Consensus